{"id":11699,"date":"2026-10-29T12:51:41","date_gmt":"2026-10-29T12:51:41","guid":{"rendered":"https:\/\/nonsensia.pl\/?p=11699"},"modified":"2026-10-21T07:56:53","modified_gmt":"2026-10-21T07:56:53","slug":"levodopa-blood-brain-barrier-lat1-transport","status":"publish","type":"post","link":"https:\/\/nonsensia.pl\/ro\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/","title":{"rendered":"Levodopa \u0219i bariera hematoencefalic\u0103: o molecul\u0103 conceput\u0103 \u00een jurul unei probleme de transport"},"content":{"rendered":"

Iat\u0103 o valoare care contrazice explica\u021bia obi\u0219nuit\u0103 din manuale. PubChem atribuie L-DOPA un XLogP3 calculat de −2,7 \u0219i o suprafa\u021b\u0103 polar\u0103 topologic\u0103 de 104 Å2<\/sup>. Pentru dopamin\u0103, acelea\u0219i calcule dau −1,0 \u0219i 66,5 Å2<\/sup>. Dup\u0103 ambii descriptori, dopamina este compusul mai pu\u021bin<\/em> polar din pereche.<\/p>\n

Cu toate acestea, dopamina administrat\u0103 \u00een circula\u021bia sanguin\u0103 nu ajunge la creier, \u00een timp ce precursorul s\u0103u biosintetic imediat ajunge. Dac\u0103 mecanismul ar fi difuzia pasiv\u0103 printr-o membran\u0103 lipidic\u0103, acest rezultat ar fi inversat. A \u00een\u021belege rela\u021bia dintre levodopa \u0219i bariera hematoencefalic\u0103 \u00eenseamn\u0103 a renun\u021ba complet la modelul difuziei.<\/p>\n

Problema levodopei la bariera hematoencefalic\u0103: un punct de control, nu un zid<\/h2>\n

Celulele endoteliale ale capilarelor cerebrale sunt sudate prin jonc\u021biuni str\u00e2nse, astfel \u00eenc\u00e2t o molecul\u0103 din plasm\u0103 nu se poate strecura printre ele. Ceea ce poate face este s\u0103 utilizeze una dintre proteinele transportoare expuse de aceste celule, iar transportorul relevant aici este LAT1, transportorul de aminoacizi neutri mari, gena SLC7A5<\/em>.<\/p>\n

LAT1 nu ac\u021bioneaz\u0103 singur. A\u0219a cum arat\u0103 Singh \u0219i Ecker \u00eentr-o recenzie din 2018 publicat\u0103 \u00een International Journal of Molecular Sciences<\/em>, acesta formeaz\u0103 un heterodimer cu glicoproteina 4F2hc (denumit\u0103 \u0219i CD98, gena SLC3A2<\/em>), cele dou\u0103 subunit\u0103\u021bi fiind unite printr-o punte disulfuric\u0103 conservat\u0103. 4F2hc ac\u021bioneaz\u0103 ca un chaperon care conduce complexul la membran\u0103. Ansamblul este independent de sodiu \u0219i de pH \u0219i func\u021bioneaz\u0103 ca un antiporter obligatoriu: pentru fiecare aminoacid neutru mare pe care \u00eel introduce, un aminoacid intracelular iese.<\/p>\n

\u00cen 2019, Yan \u0219i colaboratorii au publicat o structur\u0103 a complexului uman LAT1–4F2hc \u00een Nature<\/em>, transform\u00e2nd un model de transport dedus din cinetic\u0103 \u00eentr-un obiect cu coordonate.<\/p>\n

Lista de cerin\u021be pentru substrat pe care dopamina nu o \u00eendepline\u0219te<\/h2>\n

LAT1 recunoa\u0219te o form\u0103, nu un coeficient de parti\u021bie. Singh \u0219i Ecker enumer\u0103 patru cerin\u021be structurale pentru un ligand: o grupare carboxil liber\u0103 nesubstituit\u0103 la Cα, o grupare amino primar\u0103 nesubstituit\u0103 la Cα, un hidrogen sau un metil la Cα \u0219i o caten\u0103 lateral\u0103 neutr\u0103, hidrofob\u0103 \u0219i voluminoas\u0103. Transportul este stereospecific, favoriz\u00e2nd formele L.<\/p>\n

Compara\u021bi aceste patru condi\u021bii cu cele dou\u0103 molecule, iar paradoxul dispare.<\/p>\n\n\n\n\n\n\n\n\n\n\n
Proprietate<\/th>\nLevodopa<\/th>\nDopamina<\/th>\n<\/tr>\n<\/thead>\n
PubChem CID<\/td>\n6047<\/td>\n681<\/td>\n<\/tr>\n
Formul\u0103<\/td>\nC9<\/sub>H11<\/sub>NO4<\/sub><\/td>\nC8<\/sub>H11<\/sub>NO2<\/sub><\/td>\n<\/tr>\n
Mas\u0103 molecular\u0103<\/td>\n197,19<\/td>\n153,18<\/td>\n<\/tr>\n
XLogP3<\/td>\n−2,7<\/td>\n−1,0<\/td>\n<\/tr>\n
TPSA<\/td>\n104 Å2<\/sup><\/td>\n66.5 Å2<\/sup><\/td>\n<\/tr>\n
Carboxil α liber<\/td>\nda<\/td>\nniciun<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Dopamina este 4-(2-aminoetil)benzen-1,2-diol. Este levodopa minus o grupare carboxil. Acest COOH lips\u0103 nu este o diferen\u021b\u0103 minor\u0103 de polaritate — este elementul de recunoa\u0219tere de care LAT1 are nevoie. Dac\u0103 este \u00eendep\u0103rtat, molecula \u00eenceteaz\u0103 s\u0103 fie un aminoacid \u0219i devine o amin\u0103 pe care niciun transportor de aminoacizi nu o accept\u0103.<\/p>\n

Levodopa, formal acid (2S)-2-amino-3-(3,4-dihidroxifenil)propanoic, p\u0103streaz\u0103 scheletul intact de α-aminoacid, cu o caten\u0103 lateral\u0103 catecolic\u0103 voluminoas\u0103. Pentru LAT1, ea arat\u0103 ca tirozina sau fenilalanina purt\u00e2nd un hidroxil suplimentar.<\/p>\n

Demonstra\u021bia la nivelul barierei \u00eense\u0219i<\/h2>\n

Experimentul direct a fost publicat \u00een Brain Research<\/em> \u00een 2000 de Kageyama \u0219i colaboratorii de la Universitatea din Kyoto. Lucr\u00e2nd cu celule endoteliale din capilare cerebrale de \u0219oarece ca model in vitro de barier\u0103 hematoencefalic\u0103, ace\u0219tia au ar\u0103tat c\u0103 at\u00e2t 4F2hc, c\u00e2t \u0219i LAT1 sunt exprimate acolo \u0219i formeaz\u0103 heterodimeri \u0219i c\u0103 preluarea L-DOPA \u00een aceste celule este dependent\u0103 de timp, sensibil\u0103 la temperatur\u0103 \u0219i independent\u0103 de sodiu — semn\u0103tura unui transportor facilitat, nu a difuziei.<\/p>\n

Datele de competi\u021bie au stabilit identificarea. Aminoacizii neutri cu catene laterale voluminoase au inhibat substan\u021bial preluarea L-DOPA; aminoacizii acizi \u0219i bazici abia au influen\u021bat-o. Imunohistochimia a localizat LAT1 predominant \u00een microvasele sistemului nervos central. Autorii au concluzionat c\u0103 complexul 4F2hc\/LAT1 particip\u0103 la transportul L-DOPA prin barier\u0103.<\/p>\n

Aceast\u0103 competi\u021bie nu este un artefact de laborator. Aminoacizii neutri mari din alimenta\u021bie utilizeaz\u0103 acela\u0219i transportor, astfel \u00eenc\u00e2t transportorul care livreaz\u0103 levodopa este cel deja ocupat de leucin\u0103, izoleucin\u0103, valin\u0103, fenilalanin\u0103 \u0219i tirozin\u0103. Singh \u0219i Ecker men\u021bioneaz\u0103 aceea\u0219i inhibi\u021bie competitiv\u0103 ca tr\u0103s\u0103tur\u0103 general\u0103 a farmacologiei LAT1, iar aceasta se aplic\u0103 \u00een egal\u0103 m\u0103sur\u0103 gabapentinei, melfalanului \u0219i hormonilor tiroidieni, to\u021bi enumera\u021bi \u00een recenzie ca substraturi ale LAT1.<\/p>\n

A doua problem\u0103: molecula nu ajunge niciodat\u0103 acolo<\/h2>\n

Rezolvarea recunoa\u0219terii nu rezolv\u0103 livrarea. Decarboxilaza L-aminoacizilor aromatici, enzima care transform\u0103 levodopa \u00een dopamin\u0103 \u00een neuroni, este abundent\u0103 \u0219i \u00een afara sistemului nervos central. Prin urmare, levodopa din circula\u021bie este decarboxilat\u0103 periferic, iar catecol-O<\/em>-metiltransferaza deviaz\u0103 o alt\u0103 parte din ea c\u0103tre 3-O<\/em>-metildopa.<\/p>\n

Amploarea pierderii este izbitoare. O analiz\u0103 de farmacovigilen\u021b\u0103 din 2025 publicat\u0103 \u00een Frontiers in Pharmacology<\/em> arat\u0103 c\u0103, f\u0103r\u0103 interven\u021bie, doar aproximativ 1 % din levodopa administrat\u0103 oral ajunge la neuronii dopaminergici. Nou\u0103zeci \u0219i nou\u0103 la sut\u0103 din molecul\u0103 este consumat\u0103 \u00eenainte de a \u00eent\u00e2lni vreodat\u0103 un transportor LAT1 la nivelul barierei — iar dopamina format\u0103 periferic nu o poate urma, exact din motivul structural de mai sus.<\/p>\n

Solu\u021bia a fost administrarea concomitent\u0103 a unui inhibitor de decarboxilaz\u0103. Aceea\u0219i lucrare raporteaz\u0103 c\u0103 asocierea cu carbidopa sau benserazid\u0103 cre\u0219te disponibilitatea cerebral\u0103 de aproximativ zece ori \u0219i prelunge\u0219te timpul de \u00eenjum\u0103t\u0103\u021bire periferic al levodopei la circa 90 de minute, ceea ce reduce la r\u00e2ndul s\u0103u efectele periferice precum grea\u021ba \u0219i hipotensiunea.<\/p>\n

Structura carbidopei este ea \u00eens\u0103\u0219i instructiv\u0103. PubChem o descrie ca acid (2S)-3-(3,4-dihidroxifenil)-2-hidrazinil-2-metilpropanoic, CID 34359, C10<\/sub>H14<\/sub>N2<\/sub>O4<\/sub>. Este levodopa cu dou\u0103 modific\u0103ri deliberate: o grupare metil la Cα \u0219i, \u00een mod esen\u021bial, gruparea α-amino primar\u0103 \u00eenlocuit\u0103 cu o hidrazin\u0103. Hidrazina este cea care capteaz\u0103 cofactorul piridoxal-fosfat al enzimei. Aceasta \u00eenseamn\u0103 \u0219i c\u0103 molecula nu mai \u00eendepline\u0219te cerin\u021ba de grupare amino primar\u0103 nesubstituit\u0103 la Cα din lista de cerin\u021be pentru substratul LAT1 — \u00een concordan\u021b\u0103 cu un inhibitor destinat s\u0103 ac\u021bioneze numai la periferie.<\/p>\n

De ce a durat istoria un deceniu<\/h2>\n

Progresul clinic este de obicei datat \u00een 1967, c\u00e2nd Cotzias, Van Woert \u0219i Schiffer au publicat Aromatic Amino Acids and Modification of Parkinsonism<\/em> \u00een aranjamentul New England Journal of Medicine<\/em>, volumul 276, paginile 374–379. \u00cencerc\u0103rile anterioare produseser\u0103 rezultate inconsecvente, iar calculul de transport \u0219i metabolism de mai sus explic\u0103 o mare parte din aceast\u0103 inconsecven\u021b\u0103: un compus care pierde 99 % din el \u00eensu\u0219i \u00eenainte de a ajunge la locul de ac\u021biune are o fereastr\u0103 terapeutic\u0103 necru\u021b\u0103toare.<\/p>\n

Pentru laboratoarele care studiaz\u0103 ast\u0103zi aceast\u0103 chimie, identitatea \u0219i puritatea materialului conteaz\u0103 la fel de mult ca biologia. Catecolul este sensibil la aer, iar stereocentrul este esen\u021bial, astfel \u00eenc\u00e2t lucr\u0103rile se raporteaz\u0103 \u00een mod normal la un standard de referin\u021b\u0103 analitic<\/a> \u00eenso\u021bit de un certificat de analiz\u0103, \u0219i nu la con\u021binutul nominal de pe etichet\u0103.<\/p>\n

\u00centreb\u0103ri frecvente<\/h2>\n

De ce poate levodopa traversa bariera hematoencefalic\u0103, iar dopamina nu?<\/h3>\n

Nu pentru c\u0103 levodopa ar fi mai pu\u021bin polar\u0103 — descriptorii calcula\u021bi de PubChem o arat\u0103 mai hidrofil\u0103 dec\u00e2t dopamina. Levodopa traverseaz\u0103 pentru c\u0103 p\u0103streaz\u0103 un schelet intact de α-aminoacid, recunoscut de transportorul LAT1\/4F2hc din celulele endoteliale ale capilarelor cerebrale. Dopaminei \u00eei lipse\u0219te gruparea α-carboxil liber\u0103 de care acest transportor are nevoie, a\u0219a c\u0103 niciun transportor nu o accept\u0103.<\/p>\n

Ce este LAT1?<\/h3>\n

LAT1 este transportorul 1 de aminoacizi neutri mari, codificat de SLC7A5<\/em>. Se asociaz\u0103 cu glicoproteina 4F2hc (CD98, SLC3A2<\/em>) printr-o punte disulfuric\u0103 \u0219i func\u021bioneaz\u0103 ca antiporter obligatoriu independent de sodiu, schimb\u00e2nd aminoacizi neutri mari extracelulari cu aminoacizi intracelulari. Este puternic exprimat \u00een microvasele sistemului nervos central \u0219i transport\u0103 L-DOPA, gabapentina, melfalanul \u0219i hormonii tiroidieni.<\/p>\n

De ce se administreaz\u0103 levodopa \u00eempreun\u0103 cu carbidopa sau benserazid\u0103?<\/h3>\n

Decarboxilaza L-aminoacizilor aromatici transform\u0103 levodopa \u00een dopamin\u0103 \u00een tot organismul, nu doar \u00een creier. Analizele publicate estimeaz\u0103 frac\u021biunea de levodopa administrat\u0103 oral care ajunge la neuronii dopaminergici la aproximativ 1 % \u00een absen\u021ba unui inhibitor. Ad\u0103ugarea unui inhibitor de decarboxilaz\u0103 cu ac\u021biune periferic\u0103 cre\u0219te disponibilitatea cerebral\u0103 de aproximativ zece ori \u0219i prelunge\u0219te timpul de \u00eenjum\u0103t\u0103\u021bire periferic la circa 90 de minute.<\/p>\n

Concureaz\u0103 aminoacizii din alimenta\u021bie cu levodopa pentru transport?<\/h3>\n

Da. LAT1 transport\u0103 leucin\u0103, izoleucin\u0103, valin\u0103, fenilalanin\u0103 \u0219i tirozin\u0103, iar Kageyama \u0219i colaboratorii au ar\u0103tat c\u0103 aminoacizii neutri cu catene laterale voluminoase inhib\u0103 puternic preluarea L-DOPA \u00een celulele endoteliale ale capilarelor cerebrale, \u00een timp ce aminoacizii acizi \u0219i bazici nu o inhib\u0103. Competi\u021bia pentru un transportor comun este o caracteristic\u0103 intrinsec\u0103 a acestei c\u0103i de livrare.<\/p>\n

Referin\u021be<\/h2>\n
    \n
  1. PubChem CID 6047, Levodopa — propriet\u0103\u021bi calculate<\/a><\/li>\n
  2. PubChem CID 681, Dopamin\u0103 — propriet\u0103\u021bi calculate<\/a><\/li>\n
  3. PubChem CID 34359, Carbidopa — propriet\u0103\u021bi calculate<\/a><\/li>\n
  4. Kageyama T, et al. The 4F2hc\/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res. 2000;879:115–121<\/a><\/li>\n
  5. Singh N, Ecker GF. Insights into the structure, function, and ligand discovery of the large neutral amino acid transporter 1, LAT1. Int J Mol Sci. 2018;19(5):1278<\/a><\/li>\n
  6. Yan R, Zhao X, Lei J, Zhou Q. Structure of the human LAT1–4F2hc heteromeric amino acid transporter complex. Nature 2019;568:127–130<\/a><\/li>\n
  7. Qiu H, Liu C, Wang Z. Levodopa-induced motor complications associated with benserazide and carbidopa in Parkinson’s disease. Front Pharmacol. 2025;16:1529932<\/a><\/li>\n
  8. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic Amino Acids and Modification of Parkinsonism. N Engl J Med. 1967;276(7):374–379<\/a><\/li>\n<\/ol>\n
    \n

    Numai pentru cercetare.<\/strong> Nonsensia furnizeaz\u0103 standarde de referin\u021b\u0103 analitice pentru aplica\u021bii de laborator \u0219i de cercetare. Acest articol este publicat \u00een scopuri \u0219tiin\u021bifice \u0219i educa\u021bionale. Nu constituie un sfat medical, nu descrie nicio utilizare la om \u0219i nimic din cuprinsul s\u0103u nu trebuie interpretat ca o recomandare de a administra vreo substan\u021b\u0103 unei persoane sau unui animal.<\/p>","protected":false},"excerpt":{"rendered":"

    PubChem atribuie levodopei un XLogP3 calculat de -2,7, iar dopaminei -1,0, deci explica\u021bia standard conform c\u0103reia dopamina este pur \u0219i simplu prea polar\u0103 pentru a traversa nu poate fi corect\u0103. R\u0103spunsul real este un transportor cu o list\u0103 strict\u0103 de cerin\u021be structurale.<\/p>","protected":false},"author":517,"featured_media":11779,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[384],"tags":[],"class_list":["post-11699","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-chemistry-discovery"],"yoast_head":"\nLevodopa and the Blood-Brain Barrier: LAT1 Explained<\/title>\n<meta name=\"description\" content=\"Levodopa is more hydrophilic than dopamine, yet only levodopa reaches the brain. The reason is LAT1 recognition, not passive diffusion.\" \/>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"ro_RO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Levodopa and the Blood-Brain Barrier: LAT1 Explained\" \/>\n<meta property=\"og:description\" content=\"Levodopa is more hydrophilic than dopamine, yet only levodopa reaches the brain. The reason is LAT1 recognition, not passive diffusion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nonsensia.pl\/ro\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/\" \/>\n<meta property=\"og:site_name\" content=\"Nonsensia\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-29T12:51:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nonsensia.pl\/wp-content\/uploads\/2026\/09\/nonsensia-chemistry-discovery.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Thomas Reyner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Thomas Reyner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/\"},\"author\":{\"name\":\"Thomas Reyner\",\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/#\\\/schema\\\/person\\\/97c0a8a75ea8c654fd606679bb6d01fb\"},\"headline\":\"Levodopa and the Blood-Brain Barrier: A Molecule Designed Around a Transport Problem\",\"datePublished\":\"2026-10-29T12:51:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/\"},\"wordCount\":1446,\"publisher\":{\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nonsensia.pl\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/nonsensia-chemistry-discovery.png\",\"articleSection\":[\"Chemistry & Discovery\"],\"inLanguage\":\"ro-RO\",\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/ro\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/\",\"url\":\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/\",\"name\":\"Levodopa and the Blood-Brain Barrier: LAT1 Explained\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nonsensia.pl\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/nonsensia-chemistry-discovery.png\",\"datePublished\":\"2026-10-29T12:51:41+00:00\",\"description\":\"Levodopa is more hydrophilic than dopamine, yet only levodopa reaches the brain. The reason is LAT1 recognition, not passive diffusion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/#breadcrumb\"},\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nonsensia.pl\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/nonsensia-chemistry-discovery.png\",\"contentUrl\":\"https:\\\/\\\/nonsensia.pl\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/nonsensia-chemistry-discovery.png\",\"width\":1200,\"height\":630,\"caption\":\"Chemistry & Discovery \u2014 analytical reference standards, Nonsensia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nonsensia.pl\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Levodopa and the Blood-Brain Barrier: A Molecule Designed Around a Transport Problem\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/#website\",\"url\":\"https:\\\/\\\/nonsensia.pl\\\/\",\"name\":\"Nonsensia\",\"description\":\"NON-SENSIA...? We bring sense!\",\"publisher\":{\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nonsensia.pl\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ro-RO\"},{\"@type\":[\"Organization\",\"Place\"],\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/#organization\",\"name\":\"Nonsensia\",\"url\":\"https:\\\/\\\/nonsensia.pl\\\/\",\"logo\":{\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/#local-main-organization-logo\"},\"image\":{\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/#local-main-organization-logo\"},\"telephone\":[],\"openingHoursSpecification\":[{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Monday\",\"Tuesday\",\"Wednesday\",\"Thursday\",\"Friday\",\"Saturday\",\"Sunday\"],\"opens\":\"09:00\",\"closes\":\"17:00\"}],\"address\":{\"@type\":\"PostalAddress\",\"streetAddress\":\"ul. Marsza\u0142kowska 80\",\"postalCode\":\"00-517\",\"addressLocality\":\"Warszawa\",\"addressCountry\":\"PL\"},\"email\":\"lab@nonsensia.pl\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/#\\\/schema\\\/person\\\/97c0a8a75ea8c654fd606679bb6d01fb\",\"name\":\"Thomas Reyner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/17721409ed81a1e4666b08b23530653af17971df2e2cde4fad397c4da1e60ba7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/17721409ed81a1e4666b08b23530653af17971df2e2cde4fad397c4da1e60ba7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/17721409ed81a1e4666b08b23530653af17971df2e2cde4fad397c4da1e60ba7?s=96&d=mm&r=g\",\"caption\":\"Thomas Reyner\"},\"description\":\"Writes on spectroscopy, structural elucidation and laboratory instrumentation for Nonsensia.\",\"url\":\"https:\\\/\\\/nonsensia.pl\\\/ro\\\/author\\\/treyner\\\/\"},{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\\\/\\\/nonsensia.pl\\\/2026\\\/10\\\/29\\\/levodopa-blood-brain-barrier-lat1-transport\\\/#local-main-organization-logo\",\"url\":\"https:\\\/\\\/nonsensia.pl\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/cropped-Nonsensia_Logo-8.png\",\"contentUrl\":\"https:\\\/\\\/nonsensia.pl\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/cropped-Nonsensia_Logo-8.png\",\"width\":512,\"height\":512,\"caption\":\"Nonsensia\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Levodopa \u0219i bariera hematoencefalic\u0103: LAT1 explicat","description":"Levodopa este mai hidrofil\u0103 dec\u00e2t dopamina, totu\u0219i doar levodopa ajunge la creier. Motivul este recunoa\u0219terea de c\u0103tre LAT1, nu difuziunea pasiv\u0103.","robots":{"index":"noindex","follow":"follow"},"og_locale":"ro_RO","og_type":"article","og_title":"Levodopa and the Blood-Brain Barrier: LAT1 Explained","og_description":"Levodopa is more hydrophilic than dopamine, yet only levodopa reaches the brain. The reason is LAT1 recognition, not passive diffusion.","og_url":"https:\/\/nonsensia.pl\/ro\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/","og_site_name":"Nonsensia","article_published_time":"2026-10-29T12:51:41+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/nonsensia.pl\/wp-content\/uploads\/2026\/09\/nonsensia-chemistry-discovery.png","type":"image\/png"}],"author":"Thomas Reyner","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Thomas Reyner","Est. reading time":"7 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/#article","isPartOf":{"@id":"https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/"},"author":{"name":"Thomas Reyner","@id":"https:\/\/nonsensia.pl\/#\/schema\/person\/97c0a8a75ea8c654fd606679bb6d01fb"},"headline":"Levodopa and the Blood-Brain Barrier: A Molecule Designed Around a Transport Problem","datePublished":"2026-10-29T12:51:41+00:00","mainEntityOfPage":{"@id":"https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/"},"wordCount":1446,"publisher":{"@id":"https:\/\/nonsensia.pl\/#organization"},"image":{"@id":"https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/#primaryimage"},"thumbnailUrl":"https:\/\/nonsensia.pl\/wp-content\/uploads\/2026\/09\/nonsensia-chemistry-discovery.png","articleSection":["Chemistry & Discovery"],"inLanguage":"ro-RO","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/nonsensia.pl\/ro\/#organization"}},{"@type":"WebPage","@id":"https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/","url":"https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/","name":"Levodopa \u0219i bariera hematoencefalic\u0103: LAT1 explicat","isPartOf":{"@id":"https:\/\/nonsensia.pl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/#primaryimage"},"image":{"@id":"https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/#primaryimage"},"thumbnailUrl":"https:\/\/nonsensia.pl\/wp-content\/uploads\/2026\/09\/nonsensia-chemistry-discovery.png","datePublished":"2026-10-29T12:51:41+00:00","description":"Levodopa este mai hidrofil\u0103 dec\u00e2t dopamina, totu\u0219i doar levodopa ajunge la creier. Motivul este recunoa\u0219terea de c\u0103tre LAT1, nu difuziunea pasiv\u0103.","breadcrumb":{"@id":"https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/#breadcrumb"},"inLanguage":"ro-RO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/"]}]},{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/#primaryimage","url":"https:\/\/nonsensia.pl\/wp-content\/uploads\/2026\/09\/nonsensia-chemistry-discovery.png","contentUrl":"https:\/\/nonsensia.pl\/wp-content\/uploads\/2026\/09\/nonsensia-chemistry-discovery.png","width":1200,"height":630,"caption":"Chemistry & Discovery \u2014 analytical reference standards, Nonsensia"},{"@type":"BreadcrumbList","@id":"https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nonsensia.pl\/"},{"@type":"ListItem","position":2,"name":"Levodopa and the Blood-Brain Barrier: A Molecule Designed Around a Transport Problem"}]},{"@type":"WebSite","@id":"https:\/\/nonsensia.pl\/#website","url":"https:\/\/nonsensia.pl\/","name":"Nonsensia","description":"NON-SENSIA...? We bring sense!","publisher":{"@id":"https:\/\/nonsensia.pl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nonsensia.pl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ro-RO"},{"@type":["Organization","Place"],"@id":"https:\/\/nonsensia.pl\/#organization","name":"Nonsensia","url":"https:\/\/nonsensia.pl\/","logo":{"@id":"https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/#local-main-organization-logo"},"image":{"@id":"https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/#local-main-organization-logo"},"telephone":[],"openingHoursSpecification":[{"@type":"OpeningHoursSpecification","dayOfWeek":["Monday","Tuesday","Wednesday","Thursday","Friday","Saturday","Sunday"],"opens":"09:00","closes":"17:00"}],"address":{"@type":"PostalAddress","streetAddress":"ul. Marsza\u0142kowska 80","postalCode":"00-517","addressLocality":"Warszawa","addressCountry":"PL"},"email":"lab@nonsensia.pl"},{"@type":"Person","@id":"https:\/\/nonsensia.pl\/#\/schema\/person\/97c0a8a75ea8c654fd606679bb6d01fb","name":"Thomas Reyner","image":{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/secure.gravatar.com\/avatar\/17721409ed81a1e4666b08b23530653af17971df2e2cde4fad397c4da1e60ba7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/17721409ed81a1e4666b08b23530653af17971df2e2cde4fad397c4da1e60ba7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/17721409ed81a1e4666b08b23530653af17971df2e2cde4fad397c4da1e60ba7?s=96&d=mm&r=g","caption":"Thomas Reyner"},"description":"Scrie despre spectroscopie, elucidare structural\u0103 \u0219i instrumenta\u021bie de laborator pentru Nonsensia.","url":"https:\/\/nonsensia.pl\/ro\/author\/treyner\/"},{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/nonsensia.pl\/2026\/10\/29\/levodopa-blood-brain-barrier-lat1-transport\/#local-main-organization-logo","url":"https:\/\/nonsensia.pl\/wp-content\/uploads\/2024\/12\/cropped-Nonsensia_Logo-8.png","contentUrl":"https:\/\/nonsensia.pl\/wp-content\/uploads\/2024\/12\/cropped-Nonsensia_Logo-8.png","width":512,"height":512,"caption":"Nonsensia"}]}},"_links":{"self":[{"href":"https:\/\/nonsensia.pl\/ro\/wp-json\/wp\/v2\/posts\/11699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nonsensia.pl\/ro\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nonsensia.pl\/ro\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nonsensia.pl\/ro\/wp-json\/wp\/v2\/users\/517"}],"replies":[{"embeddable":true,"href":"https:\/\/nonsensia.pl\/ro\/wp-json\/wp\/v2\/comments?post=11699"}],"version-history":[{"count":3,"href":"https:\/\/nonsensia.pl\/ro\/wp-json\/wp\/v2\/posts\/11699\/revisions"}],"predecessor-version":[{"id":12008,"href":"https:\/\/nonsensia.pl\/ro\/wp-json\/wp\/v2\/posts\/11699\/revisions\/12008"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nonsensia.pl\/ro\/wp-json\/wp\/v2\/media\/11779"}],"wp:attachment":[{"href":"https:\/\/nonsensia.pl\/ro\/wp-json\/wp\/v2\/media?parent=11699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nonsensia.pl\/ro\/wp-json\/wp\/v2\/categories?post=11699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nonsensia.pl\/ro\/wp-json\/wp\/v2\/tags?post=11699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}